Table 6 Adverse events (safety population)
Study | Ceftaroline group | Control group | Ceftaroline group | Control group | Ceftaroline group | Control group | Ceftaroline group | Control group |
|---|---|---|---|---|---|---|---|---|
Any adverse events, n (%) | Diarrhea, n (%) | Headache, n (%) | Insomnia, n (%) | |||||
File et al............, 2011 [10] | 119/298 (39.9) | 136/308 (44.2) | 14/298 (4.7) | 7/308 (2.3) | 10/298 (3.4) | 4/308 (1.3) | 9/298 (3.0) | 6/308 (1.9) |
Low et al., 2011 [11] | 196/315 (53.7) | 145/307 (47.2) | 12/315 (3.8) | 9/307 (2.9) | 11/315 (3.5) | 5/307 (1.6) | 10/315 (3.2) | 8/307 (2.6) |
File et al, 2010 [13] | 288/613 (47.0) | 281/615 (45.7) | 26/613 (4.2) | 16/615 (2.6) | 21 /613 (3.4) | 9/615 (1.5) | 19/613 (3.1) | 14/615 (2.3) |
Zhong et al..., 2015 [14] | 172/381 (45.1) | 163/383 (42.7) | 24/381 (6.3) | 13/383 (3.4) | 6/381 (1.6) | 9/383 (2.4) | – | – |
Nausea, n (%) | Phlebitis, n (%) | Hypertension, n (%) | Hypokalaemia, n (%) | |||||
File et al, 2011 [10] | 8/298 (2.7) | 8/308 (2.6) | 7/298 (2.3) | 5/308 (1.6) | 6/298 (2.0) | 8/308 (2.6) | 4/298 (1.3) | 10/308 (3.2) |
Low et al, 2011 [11] | 6/315 (1.9) | 6/307 (2.0) | 10/315 (3.2) | 8/307 (2.6) | 8/315 (2.5) | 8/307 (2.6) | 10/315 (3.2) | 5/307 (1.6) |
File et al, 2010 [13] | 14/613 (2.3) | 14/615 (2.3) | 17/613 (2.8) | 13/615 (2.1) | 14/613 (2.3) | 16/615 (2.6) | 14/613 (2.3) | 15/615 (2.4) |
Zhong et al, 2015 [14] | 8/381 (2.1) | 3/383 (0.8) | – | – | – | – | 5/381 (1.3) | 4/383 (1.1) |